Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Pharmacy Department, CHU Dinant-Godinne UCL Namur, Université catholique de Louvain, Yvoir, Belgium.
Br J Clin Pharmacol. 2018 Nov;84(11):2600-2614. doi: 10.1111/bcp.13716. Epub 2018 Aug 17.
We aimed to develop a standardized chart review method to identify drug-related hospital admissions (DRA) in older people caused by non-preventable adverse drug reactions and preventable medication errors including overuse, underuse and misuse of medications: the DRA adjudication guide.
The DRA adjudication guide was developed based on design and test iterations with international and multidisciplinary input in four subsequent steps: literature review; evaluation of content validity using a Delphi consensus technique; a pilot test; and a reliability study.
The DRA adjudication guide provides definitions, examples and step-by-step instructions to measure DRA. A three-step standardized chart review method was elaborated including: (i) data abstraction; (ii) explicit screening with a newly developed trigger tool for DRA in older people; and (iii) consensus adjudication for causality by a pharmacist and a physician using the World Health Organization-Uppsala Monitoring Centre and Hallas criteria. A 15-member international Delphi panel reached consensus agreement on 26 triggers for DRA in older people. The DRA adjudication guide showed good feasibility of use and achieved moderate inter-rater reliability for the evaluation of 16 cases by four European adjudication pairs (71% agreement, κ = 0.41). Disagreements arose mainly for cases with potential underuse.
The DRA adjudication guide is the first standardized chart review method to identify DRA in older persons. Content validity, feasibility of use and inter-rater reliability were found to be satisfactory. The method can be used as an outcome measure for interventions targeted at improving quality and safety of medication use in older people.
我们旨在开发一种标准化的图表审查方法,以识别老年人因非预防不良反应和可预防药物错误导致的药物相关性住院(DRA),包括药物过度使用、不足使用和误用:DRA 裁决指南。
该 DRA 裁决指南是基于与国际和多学科的设计和测试迭代,分四个步骤开发的:文献综述;使用德尔菲共识技术评估内容有效性;试点测试;以及可靠性研究。
DRA 裁决指南提供了定义、示例和逐步说明,以衡量 DRA。详细阐述了一种三步标准化图表审查方法,包括:(i)数据抽象;(ii)使用新开发的老年人 DRA 触发工具进行明确筛选;以及(iii)药剂师和医生使用世界卫生组织-乌普萨拉监测中心和哈拉斯标准进行因果关系共识裁决。一个由 15 名国际德尔菲小组成员组成的小组就老年人的 26 个 DRA 触发因素达成了共识。DRA 裁决指南在评估四个欧洲裁决对 16 个案例时表现出良好的使用可行性,达到了中等的组内一致性(71%的一致性,κ=0.41)。分歧主要出现在潜在药物不足使用的案例中。
DRA 裁决指南是第一种用于识别老年人 DRA 的标准化图表审查方法。内容有效性、使用可行性和组内一致性均令人满意。该方法可作为干预措施的结果测量指标,旨在提高老年人用药的质量和安全性。